Log in

Polarityte Stock Forecast, Price & News

+0.02 (+1.96 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $1.04
50-Day Range
MA: $1.23
52-Week Range
Now: $1.04
Volume185,112 shs
Average Volume838,677 shs
Market Capitalization$40.29 million
P/E RatioN/A
Dividend YieldN/A
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:PTE



Sales & Book Value

Annual Sales$5.65 million
Book Value$1.42 per share


Net Income$-92,490,000.00
Net Margins-1,152.56%


Market Cap$40.29 million
Next Earnings Date11/10/2020 (Estimated)
+0.02 (+1.96 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PTE News and Ratings via Email

Sign-up to receive the latest news and ratings for PTE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Polarityte (NASDAQ:PTE) Frequently Asked Questions

How has Polarityte's stock price been impacted by COVID-19?

Polarityte's stock was trading at $1.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PTE shares have decreased by 2.8% and is now trading at $1.04.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Polarityte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Polarityte in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Polarityte

When is Polarityte's next earnings date?

Polarityte is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Polarityte

How were Polarityte's earnings last quarter?

Polarityte Inc (NASDAQ:PTE) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.33) EPS for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.07. The firm had revenue of $2.27 million for the quarter, compared to analysts' expectations of $0.85 million. Polarityte had a negative net margin of 1,152.56% and a negative return on equity of 179.96%. During the same period in the prior year, the business posted ($0.92) earnings per share.
View Polarityte's earnings history

What guidance has Polarityte issued on next quarter's earnings?

Polarityte issued an update on its third quarter 2020 Pre-Market earnings guidance on Monday, September, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.2 million, compared to the consensus revenue estimate of $2.85 million.

What price target have analysts set for PTE?

5 analysts have issued 12-month price objectives for Polarityte's stock. Their forecasts range from $3.00 to $6.00. On average, they expect Polarityte's stock price to reach $4.40 in the next year. This suggests a possible upside of 323.1% from the stock's current price.
View analysts' price targets for Polarityte

Are investors shorting Polarityte?

Polarityte saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 2,550,000 shares, a decline of 9.6% from the August 31st total of 2,820,000 shares. Based on an average daily trading volume, of 1,220,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 10.7% of the shares of the company are sold short.
View Polarityte's Short Interest

Who are some of Polarityte's key competitors?

What other stocks do shareholders of Polarityte own?

Who are Polarityte's key executives?

Polarityte's management team includes the following people:
  • Mr. David B. Seaburg, Chief Exec. Officer (Age 50, Pay $7.5k)
  • Dr. Edward Winslow Swanson, Chief Translational Medicine Officer & Co-Founder (Age 35, Pay $400k)
  • Mr. Paul Elliot Mann, Exec. Officer
  • Mr. Richard Hague, Pres & COO (Age 60)
  • Mr. Jacob Alexander Patterson, Interim Chief Financial Officer

What is Polarityte's stock symbol?

Polarityte trades on the NASDAQ under the ticker symbol "PTE."

Who are Polarityte's major shareholders?

Polarityte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (1.95%), FMR LLC (1.95%), Advisor Group Holdings Inc. (0.46%), Jane Street Group LLC (0.24%), Bernardo Wealth Planning LLC (0.21%) and Levin Capital Strategies L.P. (0.10%). Company insiders that own Polarityte stock include Cameron J Hoyler, David B Seaburg, Denver Lough, Edward Winslow Swanson, Jeffrey Hansen Dyer, Paul Elliot Mann, Peter A Cohen, Rainer M Erdtmann, Richard Hague and Steve Gorlin.
View institutional ownership trends for Polarityte

Which major investors are selling Polarityte stock?

PTE stock was sold by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P., FMR LLC, FMR LLC, and Advisor Group Holdings Inc.. Company insiders that have sold Polarityte company stock in the last year include Cameron J Hoyler, David B Seaburg, Denver Lough, Jeffrey Hansen Dyer, Paul Elliot Mann, Rainer M Erdtmann, and Richard Hague.
View insider buying and selling activity for Polarityte

Which major investors are buying Polarityte stock?

PTE stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Verition Fund Management LLC, and Bernardo Wealth Planning LLC. Company insiders that have bought Polarityte stock in the last two years include Edward Winslow Swanson, Paul Elliot Mann, and Peter A Cohen.
View insider buying and selling activity for Polarityte

How do I buy shares of Polarityte?

Shares of PTE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Polarityte's stock price today?

One share of PTE stock can currently be purchased for approximately $1.04.

How big of a company is Polarityte?

Polarityte has a market capitalization of $40.29 million and generates $5.65 million in revenue each year. The company earns $-92,490,000.00 in net income (profit) each year or ($3.70) on an earnings per share basis. Polarityte employs 153 workers across the globe.

What is Polarityte's official website?

The official website for Polarityte is www.polarityte.com.

How can I contact Polarityte?

Polarityte's mailing address is 123 NORTH WRIGHT BROTHERS DRIVE, SALT LAKE CITY UT, 84116. The company can be reached via phone at 385-237-2279 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.